1
|
Shiraishi K, Yoshida O, Imai Y, Akbar SMF, Sanada T, Kohara M, Miyazaki T, Kamishita T, Miyake T, Hirooka M, Tokumoto Y, Abe M, Rubido JCA, Nieto GG, Hiasa Y. Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders. Vaccines (Basel) 2023; 11:1479. [PMID: 37766155 PMCID: PMC10535445 DOI: 10.3390/vaccines11091479] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 09/05/2023] [Accepted: 09/10/2023] [Indexed: 09/29/2023] Open
Abstract
Hepatitis B vaccine induces the production of antibodies against hepatitis B surface antigen (anti-HBs) and prevents hepatitis B virus (HBV) infection. However, 5-10% of individuals cannot develop anti-HBs even after multiple vaccinations (HB vaccine non-responders). We developed an intranasal vaccine containing both HBs antigen (HBsAg) and HB core antigen (HBcAg) and mixed it with a viscosity enhancer, carboxyl vinyl polymer (CVP-NASVAC). Here, we investigated the prophylactic capacity of CVP-NASVAC in HB vaccine non-responders. Thirty-four HB vaccine non-responders were administered three doses of intranasal CVP-NASVAC. The prophylactic capacity of CVP-NASVAC was assessed by evaluating the induction of anti-HBs and anti-HBc (IgA and IgG) production, HBV-neutralization activity of sera, and induction of HBs- and HBc-specific cytotoxic T lymphocytes (CTLs). After CVP-NASVAC administration, anti-HBs and anti-HBc production were induced in 31/34 and 27/34 patients, respectively. IgA anti-HBs and anti-HBc titers significantly increased after CVP-NASVAC vaccination. HBV-neutralizing activity in vitro was confirmed in the sera of 26/29 CVP-NASVAC-administered participants. HBs- and HBc-specific CTL counts substantially increased after the CVP-NASVAC administration. Mild adverse events were observed in 9/34 participants; no serious adverse events were reported. Thus, CVP-NASVAC could be a beneficial vaccine for HB vaccine non-responders.
Collapse
Affiliation(s)
- Kana Shiraishi
- Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Toon 791-0295, Japan
| | - Osamu Yoshida
- Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Toon 791-0295, Japan
| | - Yusuke Imai
- Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Toon 791-0295, Japan
| | - Sheikh Mohammad Fazle Akbar
- Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Toon 791-0295, Japan
| | - Takahiro Sanada
- Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan
| | - Michinori Kohara
- Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan
| | | | | | - Teruki Miyake
- Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Toon 791-0295, Japan
| | - Masashi Hirooka
- Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Toon 791-0295, Japan
| | - Yoshio Tokumoto
- Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Toon 791-0295, Japan
| | - Masanori Abe
- Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Toon 791-0295, Japan
| | - Julio Cesar Aguilar Rubido
- Vaccine Division, Biomedical Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba
| | - Gerardo Guillen Nieto
- Vaccine Division, Biomedical Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba
| | - Yoichi Hiasa
- Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Toon 791-0295, Japan
| |
Collapse
|
2
|
Varotto-Boccazzi I, Epis S, Cattaneo GM, Guerrini N, Manenti A, Rubolini D, Gabrieli P, Otranto D, Zuccotti G, Montomoli E, Bandi C. Rectal Administration of Leishmania Cells Elicits a Specific, Th1-Associated IgG2a Response in Mice: New Perspectives for Mucosal Vaccination against Leishmaniasis, after the Repurposing of a Study on an Anti-Viral Vaccine Candidate. Trop Med Infect Dis 2023; 8:406. [PMID: 37624344 PMCID: PMC10458511 DOI: 10.3390/tropicalmed8080406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 07/28/2023] [Accepted: 08/05/2023] [Indexed: 08/26/2023] Open
Abstract
The mucosal immune system plays a pivotal role in the control of infections, as it represents the first line of defense against most pathogens, from respiratory viruses to intestinal parasites. Mucosal vaccination is thus regarded as a promising strategy to protect animals, including humans, from infections that are acquired by ingestion, inhalation or through the urogenital system. In addition, antigens delivered at the mucosal level can also elicit systemic immune responses. Therefore, mucosal vaccination is potentially effective also against systemic infections acquired through non-mucosal routes, for example, through the bite of hematophagous insects, as in the case of leishmaniasis, a widespread disease that affects humans and dogs. Here, we explored the potential of antigen rectal administration for the generation of anti-Leishmania immunity. Mice were immunized through rectal administration of whole cells of the model parasite Leishmania tarentolae (using a clone engineered to express the spike protein of the SARS-CoV-2 virus generated in a previous study). A specific anti-Leishmania IgG antibody response was detected. In addition, the recorded IgG2a/IgG1 ratio was higher than that of animals injected subcutaneously; therefore, suggesting a shift to a Th1-biased immune response. Considering the importance of a Th1 polarization as a protective response against Leishmania infections, we suggest that further investigation should be focused on the development of novel types of vaccines against these parasites based on rectal immunization.
Collapse
Affiliation(s)
- Ilaria Varotto-Boccazzi
- Department of Biosciences, University of Milan, 20133 Milan, Italy; (I.V.-B.); (G.M.C.); (P.G.)
- Pediatric CRC ‘Fondazione Romeo ed Enrica Invernizzi’, University of Milan, 20157 Milan, Italy;
| | - Sara Epis
- Department of Biosciences, University of Milan, 20133 Milan, Italy; (I.V.-B.); (G.M.C.); (P.G.)
- Pediatric CRC ‘Fondazione Romeo ed Enrica Invernizzi’, University of Milan, 20157 Milan, Italy;
| | - Giulia Maria Cattaneo
- Department of Biosciences, University of Milan, 20133 Milan, Italy; (I.V.-B.); (G.M.C.); (P.G.)
| | - Noemi Guerrini
- VisMederi, 53100 Siena, Italy; (N.G.); (A.M.); (E.M.)
- Department of Life Sciences, University of Siena, 53100 Siena, Italy
| | | | - Diego Rubolini
- Department of Environmental Science and Policy, University of Milan, 20133 Milan, Italy;
- Water Research Institute-National Research Council of Italy, IRSA-CNR, 20861 Brugherio, Italy
| | - Paolo Gabrieli
- Department of Biosciences, University of Milan, 20133 Milan, Italy; (I.V.-B.); (G.M.C.); (P.G.)
- Pediatric CRC ‘Fondazione Romeo ed Enrica Invernizzi’, University of Milan, 20157 Milan, Italy;
| | - Domenico Otranto
- Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy;
- Faculty of Veterinary Sciences, Bu-Ali Sina University, Hamedan 65175/4161, Iran
| | - Gianvincenzo Zuccotti
- Pediatric CRC ‘Fondazione Romeo ed Enrica Invernizzi’, University of Milan, 20157 Milan, Italy;
- Department of Biomedical and Clinical Sciences, University of Milan, 20157 Milan, Italy
| | - Emanuele Montomoli
- VisMederi, 53100 Siena, Italy; (N.G.); (A.M.); (E.M.)
- Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy
| | - Claudio Bandi
- Department of Biosciences, University of Milan, 20133 Milan, Italy; (I.V.-B.); (G.M.C.); (P.G.)
- Pediatric CRC ‘Fondazione Romeo ed Enrica Invernizzi’, University of Milan, 20157 Milan, Italy;
| |
Collapse
|
3
|
Freyre FM, Aguiar JA, Cinza Z, Figueroa N, Diaz PA, Muzio VL, Lemos G, Freyre G, Coizeau E, Rodríguez C, Pentón E, Campos M, Santos IL, Mahtab MA, Akbar SMF, Guillen GE, Aguilar JC. Impact of the Route and Schedule of Immunization on the Serological and Virological Response of Chronic Hepatitis B Patients Treated with HeberNasvac. Euroasian J Hepatogastroenterol 2023; 13:73-78. [PMID: 38222949 PMCID: PMC10785140 DOI: 10.5005/jp-journals-10018-1402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Accepted: 10/20/2023] [Indexed: 01/16/2024] Open
Abstract
HeberNasvac is a recently developed therapeutic vaccine for chronic hepatitis B (CHB) administered by intranasal (IN) and subcutaneous (SC) routes in a 14 days/10 doses schedule. To compare different schedules and routes of immunizations, a group of patients received four different vaccination regimens in a placebo-controlled factorial study. Subsequently, patients were followed for a minimum time of 48 weeks. Samples collected at the end of the follow-up were compared with initial samples. Groups I and II received the product by IN/SC routes, every 14 and 7 days, respectively. Groups III and IV were treated by SC route alone following a 14 and 7 days schedule. A group of 21 CHB patients received the vaccine in four different schedules and eight patients received placebo for a total of 29 patients enrolled. The 61.9% of vaccinees reduced their VL ≥2Log compared with baseline levels and 25% in placebo group. The 47.6% of vaccines reduced HBV levels to undetectable, 25% in placebo. HBeAg loss and seroconversion to anti-HBeAg was only achieved in vaccinees, 4 out of 9 (44.4%), and 40% (8 out of 20) developed anti-HBs response, none in placebo group. Reduction of HBsAg level in ≥1Log was achieved in the 35.0% of vaccinees and in none of the placebo-treated patients. Considering the individual and factorial analysis, significant HBV DNA reduction was detected in groups I and II, immunized by IN/SC routes. A significantly higher proportion of patients reducing VL to ≥2Log was also detected grouping the patients treated by IN/SC routes (G I + II) and grouping those inoculated every 14 days (G I + III), with 72.7% and 63.6%, respectively, compared with the placebo group (25.0%). The patients immunized every 14 days (G I + G III) also reduced the HBsAg levels compared with baseline. In conclusion, after more than 48 weeks of treatment-free follow-up, HeberNasvac-treated patients demonstrated superior responses compared with the placebo group in terms of antiviral and serological responses. The factorial analysis evidenced that the schedule combining the IN route of immunization and the frequency of 14 days resulted in the stronger antiviral and serological responses. Present results support the study of IN-only immunization schedules in future and was consistent with previous results. Long-lasting follow-ups were done to explore histological variables and the progression of serological variables in order to detect late responders. How to cite this article Freyre FM, Aguiar JA, Cinza Z, et al. Impact of the Route and Schedule of Immunization on the Serological and Virological Response of Chronic Hepatitis B Patients Treated with HeberNasvac. Euroasian J Hepato-Gastroenterol 2023;13(2):73-78.
Collapse
Affiliation(s)
- Freya Milagros Freyre
- Direction of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Jorge A Aguiar
- Direction of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Zurina Cinza
- Direction of Clinical Trials, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Nelvis Figueroa
- Direction of Clinical Trials, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Pablo Arsenio Diaz
- Direction of Clinical Trials, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Verena Lucila Muzio
- Direction of Clinical Trials, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Gilda Lemos
- Department of Regulatory Affairs, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Giselle Freyre
- Department of Regulatory Affairs, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Edelgis Coizeau
- Department of Regulatory Affairs, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Chabeli Rodríguez
- Direction of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Eduardo Pentón
- Direction of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Magalys Campos
- Direction of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Iván Luis Santos
- Direction of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Mamun Al Mahtab
- Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
| | - Sheikh Mohammad Fazle Akbar
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan; Research Center for Global and Local Infectious Diseases, Oita University, Oita, Japan; Miyakawa Memorial Research Foundation, Tokyo, Japan
| | - Gerardo E Guillen
- Direction of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Julio Cesar Aguilar
- Direction of Biomedical Research, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| |
Collapse
|
4
|
Sanada T, Yamamoto N, Kayesh MEH, Tsukiyama-Kohara K, Hasegawa H, Miyazaki T, Takano JI, Shiogama Y, Yasutomi Y, Goh Y, Yoshida O, Hiasa Y, Kohara M. Intranasal vaccination with HBs and HBc protein combined with carboxyl vinyl polymer induces strong neutralizing antibody, anti-HBs IgA, and IFNG response. Biochem Biophys Res Commun 2019; 520:86-92. [PMID: 31582218 DOI: 10.1016/j.bbrc.2019.09.072] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2019] [Accepted: 09/18/2019] [Indexed: 12/22/2022]
Abstract
Hepatitis B virus (HBV) infection causes acute and chronic hepatitis, which is a major public health concern worldwide. Immunization methods incorporating hepatitis B surface-small (HBs-S) antigen and hepatitis B core antigen (HBc) have been proposed as candidate therapeutic vaccines, but the elimination of existing HBV infection remains a challenge. To enhance the efficacy of HBs and HBc vaccination, we investigated HBs-large (HBs-L) as an immunogen, and carboxyl vinyl polymer (CVP) as an excipient. HBs-S or HBs-L, in combination with HBc antigen, was administered subcutaneously (without CVP) or intranasally (with or without CVP) for the evaluation of immune response in the tree shrew, which is considered to be a suitable small animal model of HBV infection. Immunization with HBs-L antigen by either route induced a rapid IgG response. Intranasal immunization with HBs-S or HBs-L and HBc formulated with CVP strongly induced neutralizing antibody activity, IgA response, and HBc-specific expression of the interferon gamma-encoding gene. These data indicated the potential of HBs-L and HBc intranasal immunization with CVP, not only as a therapeutic vaccine, but also as a prophylactic vaccine candidate.
Collapse
Affiliation(s)
- Takahiro Sanada
- Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan
| | - Naoki Yamamoto
- Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan
| | | | - Kyoko Tsukiyama-Kohara
- Joint Faculty of Veterinary Medicine, Kagoshima University, Korimoto, Kagoshima-city, Kagoshima 890-8580, Japan
| | - Hideki Hasegawa
- Department of Pathology, National Institute of Infectious Diseases, Toyama, Shinjuku-ku, Tokyo 162-8640, Japan; Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen, Musashimurayama-city, Tokyo 208-0011, Japan
| | - Takashi Miyazaki
- Toko Yakuhin Kogyo Co., Ltd., 20 Tsuji, Tateyama-machi, Toyama, 930-0211, Japan
| | - Jun-Ichiro Takano
- Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Health and Nutrition, Hachimandai, Tsukuba, Ibaraki, 305-0843, Japan
| | - Yumiko Shiogama
- Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Health and Nutrition, Hachimandai, Tsukuba, Ibaraki, 305-0843, Japan
| | - Yasuhiro Yasutomi
- Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Health and Nutrition, Hachimandai, Tsukuba, Ibaraki, 305-0843, Japan
| | - Yasumasa Goh
- Beacle, Inc., Yoshida-kawaracho, Sakyo-ku, Kyoto, 606-8305, Japan
| | - Osamu Yoshida
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shizukawa, Toon, Ehime, 791-0295, Japan
| | - Yoichi Hiasa
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shizukawa, Toon, Ehime, 791-0295, Japan
| | - Michinori Kohara
- Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan.
| |
Collapse
|
5
|
Lazo Vázquez L, Gil González L, Marcos López E, Pérez Fuentes Y, Cervetto de Armas L, Brown Richards E, Valdés Prado I, Suzarte Portal E, Cobas Acosta K, Yaugel Novoa M, Romero Fernández Y, Guillén Nieto G, Hermida Cruz L. Evaluation in Mice of the Immunogenicity of a Tetravalent Subunit Vaccine Candidate Against Dengue Virus Using Mucosal and Parenteral Immunization Routes. Viral Immunol 2017; 30:350-358. [PMID: 28418786 DOI: 10.1089/vim.2016.0150] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Our group has developed a subunit vaccine candidate against Dengue virus (DENV) based on two different viral regions, the domain III of the envelope protein and the capsid protein. The chimeric proteins for each serotype (DIIIC1-4), aggregated with the oligodeoxynucleotide 39 M, form the tetravalent formulation named Tetra DIIIC. Tetra DIIIC induces a protective immune response in mice when it is inoculated by intraperitoneal route. However, if children are the main targets for a DENV vaccine, then a needle-free route of administration should be attractive and advantageous. In this study, we evaluated for the first time, in vivo, a vaccine candidate against DENV based on recombinant proteins using the intranasal route. After three doses of Tetra DIIIC in mice, we measured the humoral immune response against the four DENV serotypes and the corresponding recombinant proteins. Moreover, the functionality of these antibodies was evaluated through a plaque reduction neutralization test. Finally, to assess the cellular immune response induced, we measured the IFN-γ-levels secreted by spleen cells after in vitro stimulation with DENV. The results presented in this study indicate that the intranasal immunization with Tetra DIIIC favors the generation of DENV-specific cell-mediated immunity. On the other hand, the immunization using intraperitoneal and intranasal routes, simultaneously, generate functional antibodies (anti-DIIIC and anti-DENV) and an in vitro response of IFN-γ secretion.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Iris Valdés Prado
- Center for Genetic Engineering and Biotechnology (CIGB) , Havana, Cuba
| | | | | | | | | | | | | |
Collapse
|
6
|
Ward H, Tang L, Poonia B, Kottilil S. Treatment of hepatitis B virus: an update. Future Microbiol 2016; 11:1581-1597. [PMID: 27855500 DOI: 10.2217/fmb-2016-0128] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Chronic hepatitis B virus infection is a global health concern as it affects over 240 million people worldwide and an estimated 686,000 people die annually as a result of complications of the disease. With the development of newer antiviral drugs, viral suppression of HBV is achievable, however elimination of HBV from infected individuals (functional cure) remains an issue. Due to persistence of HBV DNA (cccDNA) in infected cells, chronically infected patients who discontinue therapy prior to HBsAg loss or seroconversion are likely to relapse. Several novel therapeutic strategies are being researched and studied in clinical trials. Here we review these novel strategies to achieve sustained cure or elimination of HBV. These strategies include the targeting of the host or viral factors required for viral persistence as well as therapeutic vaccines.
Collapse
Affiliation(s)
- Haley Ward
- Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
| | - Lydia Tang
- Division of Clinical Care & Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Bhawna Poonia
- Division of Clinical Care & Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Shyam Kottilil
- Division of Clinical Care & Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| |
Collapse
|
7
|
Russell MW, Whittum-Hudson J, Fidel PL, Hook EW, Mestecky J. Immunity to Sexually Transmitted Infections. Mucosal Immunol 2015. [DOI: 10.1016/b978-0-12-415847-4.00112-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
8
|
Trujillo H, Blanco A, García D, Freyre F, Aguiar J, Lobaina Y, Aguilar JC. Optimization of a Therapeutic Vaccine Candidate by Studying Routes, Immunization Schedules and Antigen Doses in HBsAg-positive Transgenic Mice. Euroasian J Hepatogastroenterol 2014; 4:70-78. [PMID: 29699351 PMCID: PMC5913899 DOI: 10.5005/jp-journals-10018-1105] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2014] [Accepted: 08/19/2014] [Indexed: 01/18/2023] Open
Abstract
Hepatitis B core antigens (HBcAg) and hepatitis B surface antigens (HBsAg) are the main structural antigens of hepatitis B virus (HBV). Both antigens are potent immunogens for experimental animals as well as in acutely infected patients. A novel formulation based on the combination of HBsAg and HBcAg has been developed as a therapeutic vaccine candidate, aimed at inducing an immune response capable of controlling the infection. An immunization schedule was conducted to evaluate the immunogenicity of this formulation after simultaneous immunization by the intranasal and parenteral routes using different schedules and doses. Humoral and cellular immune responses generated in blood and spleen were evaluated by engyme-linked immunosorbent assay (ELISA) and enzyme-liked immunospot (ELISPOT) assays respectively. A first experiment evaluated two groups of mice simultaneously immunized by intranasal (IN) and subcutaneous (SC) routes, one including alum by SC route and, in the other, the formulation was injected without adjuvant. As a result, alum adjuvant did not increase the immunogenicity under the studied conditions. In fact, the group without alum induced the most potent immune response. The immune response was enhanced by combining IN and SC immunization compared to the SC route alone. In a second experiment, mice were immunized by different mucosal routes at the same time, and compared to the simultaneously (IN/SC) immunized groups. It was demonstrated that there is no improvement on the resulting immune response by using multiple routes of immunizations simultaneously; however, the increase of the antigen dose induced a superior immune response. Interestingly, the increase of antigen dose only by SC route did not favor the resulting immunogenicity. In conclusion, the use of HBsAg transgenic mice has proven useful to optimize the formulation, avoiding the unnecessary use of alum as adjuvant as well as provided information of the role of different mucosal immunization routes and antigen dose on the resulting immune response. How to cite this article: Trujillo H, Blanco A, García D, Freyre F, Aguiar J, Lobaina Y, Aguilar JC. Optimization of a Therapeutic Vaccine Candidate by Studying Routes, Immunization Schedules and Antigen Doses in HBsAg-positive Transgenic Mice. Euroasian J Hepato-Gastroenterol 2014;4(2):70-78.
Collapse
Affiliation(s)
- H Trujillo
- Hepatitis B Department, Biomedical Research Unit, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - A Blanco
- Animal Facilities, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - D García
- Hepatitis B Department, Biomedical Research Unit, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - F Freyre
- Hepatitis B Department, Biomedical Research Unit, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - J Aguiar
- Hepatitis B Department, Biomedical Research Unit, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - Y Lobaina
- Hepatitis B Department, Biomedical Research Unit, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| | - J C Aguilar
- Hepatitis B Department, Biomedical Research Unit, Center for Genetic Engineering and Biotechnology, Havana, Cuba
| |
Collapse
|
9
|
Abstract
Chronic HBV infection is a major public health concern affecting over 240 million people worldwide. Although suppression of HBV replication is achieved in the majority of patients with currently available newer antivirals, discontinuation of therapy prior to hepatitis B surface antigen loss or seroconversion is associated with relapse of HBV in the majority of cases. Thus, new therapeutic modalities are needed to achieve eradication of the virus from chronically infected patients in the absence of therapy. The basis of HBV persistence includes viral and host factors. Here, we review novel strategies to achieve sustained cure or elimination of HBV. The novel approaches include targeting the viral and or host factors required for viral persistence, and novel immune-based therapies, including therapeutic vaccines.
Collapse
Affiliation(s)
- Rama Kapoor
- Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research Inc., (formerly SAIC-Frederick, Inc.) Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA ; Laboratory of Immunoregulation, National Institute of Allergy & Infectious Diseases, NIH, Department of Health & Human Services, Bethesda, MD 20892, USA
| | - Shyam Kottilil
- Laboratory of Immunoregulation, National Institute of Allergy & Infectious Diseases, NIH, Department of Health & Human Services, Bethesda, MD 20892, USA
| |
Collapse
|
10
|
García-Díaz D, Rodríguez I, Santisteban Y, Márquez G, Terrero Y, Brown E, Iglesias E. Th2-Th1 shift with the multiantigenic formulation TERAVAC-HIV-1 in Balb/c mice. Immunol Lett 2012. [PMID: 23183092 DOI: 10.1016/j.imlet.2012.11.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
In chronic HIV infection a progressive Th1 to Th2/Th0 cytokine-profile shift is related to disease progression. One of the possible benefits of a therapeutic vaccination might be to counterbalance this phenomenon to allow viral replication control under a Th1-type immune response. TERAVAC-HIV-1 is a multiantigenic formulation vaccine candidate against HIV-1 which comprises the recombinant protein CR3 that contains T cell epitopes and the surface and nucleocapsid antigens of Hepatitis B Virus (HBV). Previous studies showed that such virus like particles of the HBV provide a Th1 adjuvant effect. The present studies examined the capacity of TERAVAC to elicit a Th1 response in the presence of an ongoing HIV-specific Th2-type response in Balb/c mice. To examine this issue, we injected subcutaneously the animals with CR3 or viral lysate in alum which resulted in a Th2-type response. The CR3-specific Th2-type response was verified by induction of IL-4 and IL-10 secretion in ex vivo stimulated splenocytes without secretion of IFN-γ and IgG2a antibodies in serum. Further subcutaneous and simultaneous subcutaneous-nasal immunizations of the same mice with TERAVAC promoted IFN-γ secretion and production of IgG2a antibodies in accordance with a Th1-type response. This result suggests a therapeutic benefit of this vaccine candidate in the restoration of the Th1-type HIV-specific cellular response in seropositive patients.
Collapse
Affiliation(s)
- Darien García-Díaz
- Centro de Ingeniería Genética y Biotecnología (CIGB), P.O. Box 6162, Havana 10600, Cuba
| | | | | | | | | | | | | |
Collapse
|
11
|
Iglesias E, García D, Márquez G, Prieto YC, Sánchez J, Trimiño L, Soria Y, García D. Two mucosal-parenteral schedules to coadminister a multiantigenic formulation against HIV-1 in Balb/c mice. Int Immunopharmacol 2012; 12:487-93. [PMID: 22240123 DOI: 10.1016/j.intimp.2011.12.026] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2011] [Revised: 12/29/2011] [Accepted: 12/30/2011] [Indexed: 11/27/2022]
Abstract
Previous studies showed that simultaneous immunization through the nasal (IN) and subcutaneous (SC) route of a multiantigenic formulation induced a Th1 anti-HIV humoral and cellular immune responses. The formulation was comprised of a recombinant protein of HIV-1 (named CR3; Cellular Response number 3) and the surface and nucleocapsid antigens of hepatitis B virus. This study asks whether four times simultaneous administration through the IN and SC routes (SC+IN) of the multiantigenic formulation induces a similar systemic and mucosal immune responses than two sequential IN priming and two SC boosting (2IN&2SC) inoculations in mice. To answer this question, we tested the same total dose of each antigen per animal in both schedules of inoculation. We found that SC+IN and 2IN&2SC coadministration induced comparable levels of CR3(HIV)-specific IFN-γ-secreting cells and CD8+ cells proliferation in the systemic compartment of animals. Consistent with these findings, a similar Th1 profile considering anti-CR3 IgG1:IGg2a ratio was observed. Additionally, the level of IgG antibodies and the frequency of seroconverting animals in vagina were not different. However, in the case of IgA antibodies the same parameters were significantly higher in the SC+IN group. We also found important level of HBsAg-specific antibodies in serum and vaginal washes.
Collapse
Affiliation(s)
- Enrique Iglesias
- Centro de Ingeniería Genética y Biotecnología (CIGB), P.O. Box 6162, Havana 10600, Cuba.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Farnós O, Fernández E, Chiong M, Parra F, Joglar M, Méndez L, Rodríguez E, Moya G, Rodríguez D, Lleonart R, González EM, Alonso A, Alfonso P, Suárez M, Rodríguez MP, Toledo JR. Biochemical and structural characterization of RHDV capsid protein variants produced in Pichia pastoris: Advantages for immunization strategies and vaccine implementation. Antiviral Res 2009; 81:25-36. [DOI: 10.1016/j.antiviral.2008.08.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2008] [Revised: 08/25/2008] [Accepted: 08/28/2008] [Indexed: 11/30/2022]
|
13
|
Makidon PE, Bielinska AU, Nigavekar SS, Janczak KW, Knowlton J, Scott AJ, Mank N, Cao Z, Rathinavelu S, Beer MR, Wilkinson JE, Blanco LP, Landers JJ, Baker JR. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One 2008; 3:e2954. [PMID: 18698426 PMCID: PMC2496893 DOI: 10.1371/journal.pone.0002954] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2008] [Accepted: 07/23/2008] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Hepatitis B virus infection remains an important global health concern despite the availability of safe and effective prophylactic vaccines. Limitations to these vaccines include requirement for refrigeration and three immunizations thereby restricting use in the developing world. A new nasal hepatitis B vaccine composed of recombinant hepatitis B surface antigen (HBsAg) in a novel nanoemulsion (NE) adjuvant (HBsAg-NE) could be effective with fewer administrations. METHODOLOGY AND PRINCIPAL FINDINGS Physical characterization indicated that HBsAg-NE consists of uniform lipid droplets (349+/-17 nm) associated with HBsAg through electrostatic and hydrophobic interactions. Immunogenicity of HBsAg-NE vaccine was evaluated in mice, rats and guinea pigs. Animals immunized intranasally developed robust and sustained systemic IgG, mucosal IgA and strong antigen-specific cellular immune responses. Serum IgG reached > or = 10(6) titers and was comparable to intramuscular vaccination with alum-adjuvanted vaccine (HBsAg-Alu). Normalization showed that HBsAg-NE vaccination correlates with a protective immunity equivalent or greater than 1000 IU/ml. Th1 polarized immune response was indicated by IFN-gamma and TNF-alpha cytokine production and elevated levels of IgG(2) subclass of HBsAg-specific antibodies. The vaccine retains full immunogenicity for a year at 4 degrees C, 6 months at 25 degrees C and 6 weeks at 40 degrees C. Comprehensive pre-clinical toxicology evaluation demonstrated that HBsAg-NE vaccine is safe and well tolerated in multiple animal models. CONCLUSIONS Our results suggest that needle-free nasal immunization with HBsAg-NE could be a safe and effective hepatitis B vaccine, or provide an alternative booster administration for the parenteral hepatitis B vaccines. This vaccine induces a Th1 associated cellular immunity and also may provide therapeutic benefit to patients with chronic hepatitis B infection who lack cellular immune responses to adequately control viral replication. Long-term stability of this vaccine formulation at elevated temperatures suggests a direct advantage in the field, since potential excursions from cold chain maintenance could be tolerated without a loss in therapeutic efficacy.
Collapse
Affiliation(s)
- Paul E. Makidon
- Michigan Nanotechnology Institute for Medicine and Biological Sciences (M-NIMBS), University of Michigan, Ann Arbor, Michigan, United States of America
- Unit for Laboratory Animal Medicine (ULAM), University of Michigan, Ann Arbor, Michigan, United States of America
| | - Anna U. Bielinska
- Michigan Nanotechnology Institute for Medicine and Biological Sciences (M-NIMBS), University of Michigan, Ann Arbor, Michigan, United States of America
| | - Shraddha S. Nigavekar
- Michigan Nanotechnology Institute for Medicine and Biological Sciences (M-NIMBS), University of Michigan, Ann Arbor, Michigan, United States of America
| | - Katarzyna W. Janczak
- Michigan Nanotechnology Institute for Medicine and Biological Sciences (M-NIMBS), University of Michigan, Ann Arbor, Michigan, United States of America
| | - Jessica Knowlton
- Michigan Nanotechnology Institute for Medicine and Biological Sciences (M-NIMBS), University of Michigan, Ann Arbor, Michigan, United States of America
| | - Alison J. Scott
- Michigan Nanotechnology Institute for Medicine and Biological Sciences (M-NIMBS), University of Michigan, Ann Arbor, Michigan, United States of America
| | - Nicholas Mank
- Michigan Nanotechnology Institute for Medicine and Biological Sciences (M-NIMBS), University of Michigan, Ann Arbor, Michigan, United States of America
| | - Zhengyi Cao
- Michigan Nanotechnology Institute for Medicine and Biological Sciences (M-NIMBS), University of Michigan, Ann Arbor, Michigan, United States of America
| | - Sivaprakash Rathinavelu
- Michigan Nanotechnology Institute for Medicine and Biological Sciences (M-NIMBS), University of Michigan, Ann Arbor, Michigan, United States of America
| | - Michael R. Beer
- Michigan Nanotechnology Institute for Medicine and Biological Sciences (M-NIMBS), University of Michigan, Ann Arbor, Michigan, United States of America
| | - J. Erby Wilkinson
- Unit for Laboratory Animal Medicine (ULAM), University of Michigan, Ann Arbor, Michigan, United States of America
| | - Luz P. Blanco
- Michigan Nanotechnology Institute for Medicine and Biological Sciences (M-NIMBS), University of Michigan, Ann Arbor, Michigan, United States of America
| | - Jeffrey J. Landers
- Michigan Nanotechnology Institute for Medicine and Biological Sciences (M-NIMBS), University of Michigan, Ann Arbor, Michigan, United States of America
| | - James R. Baker
- Michigan Nanotechnology Institute for Medicine and Biological Sciences (M-NIMBS), University of Michigan, Ann Arbor, Michigan, United States of America
| |
Collapse
|
14
|
Bandurska K, Brodzik R, Spitsin S, Kohl T, Portocarrero C, Smirnov Y, Pogrebnyak N, Sirko A, Koprowski H, Golovkin M. Plant-produced hepatitis B core protein chimera carrying anthrax protective antigen domain-4. Hybridoma (Larchmt) 2008; 27:241-7. [PMID: 18707542 DOI: 10.1089/hyb.2008.0008] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The hepatitis B core antigen (HBcAg) can generate a strong immune response and is recognized as an effective carrier for foreign epitopes. The domain-4 epitope of the anthrax protective antigen (PA-D4) plays an essential role in generating protective immunity against virulent Bacillus anthracis. Here we report the successful production of a recombinant protein comprised of the antigenic PA-D4 integrated into the c/e1 loop of HBcAg in transgenic low-alkaloid Nicotiana tabacum. Sera of mice injected with the plant-derived purified HB/PA-D4 protein exhibited significant anti-PA- and anti-HBcAg-specific IgG titers; however, formation of virus-like particles (VLP) was not observed. These data support the feasibility of producing complex protein chimeras in plants.
Collapse
Affiliation(s)
- Katarzyna Bandurska
- Biotechnology Foundation Laboratories, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2008; 15:852-8. [PMID: 18367580 DOI: 10.1128/cvi.00382-07] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
The hepatitis B virus core (HBc) virus-like particle (VLP) is known as one of the most immunogenic antigens and carrier vehicles in different immunization strategies. Recent findings are suggesting the potential of the HBc VLPs as an oral immunogen. Here, we focus on the induction of serum humoral responses by oral administration of HBc VLPs in preparations substantially free of lipopolysaccharide and immunomodulating encapsidated RNA. The full-length HBc antigen was used, because the C-terminal arginine-rich tail may contribute to the immunogenicity of the antigen as the region is involved in cell surface heparan sulfate binding and internalization of the protein. Serum antibody levels and isotypes were determined following oral administration of the HBc VLPs with the perspective of using the HBc VLP as an immunostimulatory and carrier molecule for epitopes of blood-borne diseases in oral immunization vaccination strategies. Following oral administration of the HBc VLP preparations to mice, a strong serum humoral response was induced with mainly immunoglobulin G2a (IgG2a) antibodies, pointing toward a Th1 response which is essential in the control of intracellular pathogens. Intraperitoneal immunization with the HBc VLP induced a stronger, mixed Th1/Th2 response. Finally, a comparison was made with the induced serum humoral response following oral administration of the recombinant cholera toxin B pentamer, a commonly used oral immunogen. These immunizations, in contrast, induced predominantly antibodies of the IgG1 isotype, indicative of a Th2 response. These data suggest that the HBc VLP can be an interesting carrier molecule in oral vaccine development.
Collapse
|
16
|
Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm 2008; 69:405-16. [PMID: 18364251 DOI: 10.1016/j.ejpb.2008.01.019] [Citation(s) in RCA: 115] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2007] [Revised: 12/28/2007] [Accepted: 01/15/2008] [Indexed: 11/24/2022]
Abstract
Alginate coated chitosan nanoparticles were previously developed with the aim of protecting the antigen, adsorbed on the surface of those chitosan nanoparticles, from enzymatic degradation at mucosal surfaces. In this work, this new delivery system was loaded with the recombinant hepatitis B surface antigen (HBsAg) and applied to mice by the intranasal route. Adjuvant effect of the delivery system was studied by measuring anti-HBsAg IgG in serum, anti-HBsAg sIgA in faeces extracts or nasal and vaginal secretions and interferon-gamma production in supernatants of the spleen cells. The mice were primed with 10 microg of the vaccine associated or not with nanoparticles and associated or not with 10 microg CpG oligodeoxynucleotide (ODN) followed by two sequential boosts at three week intervals. The association of HBsAg with the alginate coated chitosan nanoparticles, administered intranasally to the mice, gave rise to the humoral mucosal immune response. Humoral systemic immune response was not induced by the HBsAg loaded nanoparticles alone. The generation of Th1-biased antigen-specific systemic antibodies, however, was observed when HBsAg loaded nanoparticles were applied together with a second adjuvant, the immunopotentiator, CpG ODN. Moreover, all intranasally vaccinated groups showed higher interferon-gamma production when compared to naïve mice.
Collapse
|
17
|
Ma Y, Ma AG, Peng Z. A potential immunotherapy approach: mucosal immunization with an IL-13 peptide-based virus-like particle vaccine in a mouse asthma model. Vaccine 2007; 25:8091-9. [PMID: 17935839 DOI: 10.1016/j.vaccine.2007.09.009] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2007] [Revised: 08/30/2007] [Accepted: 09/03/2007] [Indexed: 01/17/2023]
Abstract
Interleukin (IL)-13 is critical in asthma pathogenesis. Previously, we have developed an IL-13 peptide-based vaccine and confirmed that subcutaneous immunization with the vaccine suppressed airway allergic inflammatory responses in a mouse asthma model. In the present study, we sought to test if mucosal immunization with the vaccine could be a potential approach, by inducing specific autoantibodies of both local IgA in the airway and systemic IgG in serum, to provide an overall suppression of redundant IL-13 effects. The results show that intranasal vaccination induces IL-13-specific IgA responses in multiple mucosal tissues and higher titers of IgG in serum than subcutaneous vaccination. This approach leads to a more effective suppression of ovalbumin-driven Th2 patterns of antibody responses and airway IL-13 and eosinophil accumulation than subcutaneous immunization, even when the induced IL-13 IgG responses were at a similar level. In conclusion, mucosal vaccination may be an innovative potential approach in the treatment of asthma.
Collapse
Affiliation(s)
- Yanbing Ma
- Department of Pediatrics and Child Health, University of Manitoba, 532-715 McDermot Avenue, Winnipeg, Canada R3E 3P4
| | | | | |
Collapse
|
18
|
Iglesias E, Franch O, Carrazana Y, Lobaina Y, García D, Sanchez J, García J, Urquiza D, Muzio V, Guillén G, Aguilar JC. Influence of aluminum-based adjuvant on the immune response to multiantigenic formulation. Viral Immunol 2007; 19:712-21. [PMID: 17201666 DOI: 10.1089/vim.2006.19.712] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Several adjuvants have been described and tested in humans. However, the aluminum-based adjuvants remain the most widely used component in vaccines today. Emerging data suggest that aluminum phosphate and aluminum hydroxide adjuvants do not promote a strong commitment to the helper T cell type 2 (Th2) pathway when they are coadministered with some Th1 adjuvants. In this regard, subtle differences between both aluminum-based adjuvants have been demonstrated. We have previously shown that subcutaneous immunization, in aluminum phosphate, of a mixture comprising the surface and core antigens of hepatitis B virus (HBV) and the multiepitopic protein CR3 of human immunodeficiency virus type 1 elicits a CR3-specific Th1 immune response. In these experiments, the antigens were adjuvated at the same time. As the final selection of the best adjuvant should be based on experimental evidence, we asked whether aluminum hydroxide allows a better Th1 immune deviation than aluminum phosphate. We also studied several ways to mix the antigens and the impact on CR3-specific interferon (IFN)-gamma secretion. Our findings indicate that aluminum hydroxide allows better Th1 immunodeviation than aluminum phosphate adjuvant for the mixture of HBV antigens and CR3. In addition, CR3-specific IFN-gamma secretion of the various formulations tested was the same irrespective of the order in which the antigens were combined.
Collapse
|
19
|
Betancourt AA, Delgado CAG, Estévez ZC, Martínez JC, Ríos GV, Aureoles-Roselló SRM, Zaldívar RA, Guzmán MA, Baile NF, Reyes PAD, Ruano LO, Fernández AC, Lobaina-Matos Y, Fernández AD, Madrazo AIJ, Martínez MIA, Baños ML, Alvarez NP, Baldo MD, Mestre RES, Pérez MVP, Martínez MEP, Escobar DA, Guanche MJC, Cáceres LM, Betancourt RS, Rando EH, Nieto GEG, González VLM, Rubido JCA. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis 2007; 11:394-401. [PMID: 17257877 DOI: 10.1016/j.ijid.2006.09.010] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2006] [Revised: 09/06/2006] [Accepted: 09/13/2006] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND The nasal vaccine candidate (NASVAC), comprising hepatitis B virus (HBV) surface (HBsAg) and core antigens (HBcAg), has been shown to be highly immunogenic in animal models. METHODS A phase I double-blinded, placebo-controlled randomized clinical trial was carried out in 19 healthy male adults with no serologic markers of immunity/infection to HBV. This study was aimed at exploring the safety and immunogenic profile of nasal co-administration of both HBV recombinant antigens. The trial was performed according to Good Clinical Practice guidelines. Participants ranged in age from 18 to 45 years and were randomly allocated to receive a mixture of 50 microg HBsAg and 50 microg HBcAg or 0.9% physiologic saline solution, as a placebo, via nasal spray in a five-dose schedule at 0, 7, 15, 30, and 60 days. A total volume of 0.5 ml was administered in two dosages of 125 microl per nostril. Adverse events were actively recorded 1 h, 6 h, 12 h, 24 h, 48 h, 72 h, 7 days and 30 days after each dose. Anti-HBs and anti-HBc titers were evaluated using corresponding ELISA kits at days 30 and 90. RESULTS The vaccine candidate was safe and well tolerated. Adverse reactions included sneezing (34.1%), rhinorrhea (12.2%), nasal stuffiness (9.8%), palate itching (9.8%), headache (9.8%), and general malaise (7.3%). These reactions were all self-limiting and mild in intensity. No severe or unexpected events were recorded during the trial. The vaccine elicited anti-HBc seroconversion in 100% of subjects as early as day 30 of the immunization schedule, while a seroprotective anti-HBs titer (>or=10 IU/l) was at a maximum at day 90 (75%). All subjects in the placebo group remained seronegative during the trial. CONCLUSION The HBsAg-HBcAg vaccine candidate was safe, well tolerated and immunogenic in this phase I study in healthy adults. To our knowledge, this is the first demonstration of safety and immunogenicity for a nasal vaccine candidate comprising HBV antigens.
Collapse
Affiliation(s)
- Arístides Aguilar Betancourt
- Vaccine Division, Vaccine Clinical Trials Department, Center for Genetic Engineering and Biotechnology, PO Box 6162, Cubanacán, Playa, Havana City, Cuba.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Iglesias E, Thompson R, Carrazana Y, Lobaina Y, García D, Sánchez J, García J, Cruz O, Brown E, Martin A, Muzio VL, Aguilar JC. Coinoculation with hepatitis B surface and core antigen promotes a Th1 immune response to a multiepitopic protein of HIV-1. Immunol Cell Biol 2006; 84:174-83. [PMID: 16519735 DOI: 10.1111/j.1440-1711.2005.01408.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
It has been defined that strong and multispecific cellular immune responses correlate with a better prognosis during the course of chronic diseases. A cross-enhancing effect on the resulting immune response obtained by the coadministration of recombinant hepatitis B virus (HBV) surface and core Ag was recently observed. With the objective of studying the effect of such Ag on the immune response to coinoculated heterologous Ag and vice versa, several formulations containing the recombinant HBV Ag and a multiepitopic protein (CR3) composed by CTL and Th epitopes from HIV-1 were evaluated by s.c. and mucosal administration. Combinations of two and three Ag were evaluated for cellular and humoral immune responses. The results showed that the best Ag combination for nasal immunization was the mixture comprising the CR3 recombinant HIV protein and both HBV Ag. Similarly, it was also the best formulation for s.c. immunization in aluminium phosphate adjuvant. In conclusion, it is possible to induce a Th1 stimulation of the cellular immune response specific for a HIV-based recombinant protein by formulating this Ag with the recombinant HBV Ag.
Collapse
|
21
|
Gathuru JK, Koide F, Ragupathi G, Adams JL, Kerns RT, Coleman TP, Livingston PO. Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity. Vaccine 2005; 23:4727-33. [PMID: 15978705 DOI: 10.1016/j.vaccine.2005.05.007] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2004] [Accepted: 05/16/2005] [Indexed: 11/25/2022]
Abstract
MUC1 is expressed at the cell surface of epithelial cancers. We have shown previously that MUC1 conjugated to keyhole limpet hemocyanin (KLH) plus the saponin immunological adjuvant QS-21 induces consistent high titer IgM and IgG antibodies in patients after treatment of their primary or metastatic cancers. KLH however is poorly soluble and heterogeneous making it difficult to work with, and we hypothesize that changing carrier proteins mid-way through a vaccination schedule would further increase antibody titers. Consequently, there is need for an alternative potent carrier protein. Duck Hepatitis B core antigen (DHBcAg) has a molecular weight of approximately 25kDa and is easily purified as a single band, but it self aggregates into particles of approximately 6.4x10(6)Da. Consequently, it is highly immunogenic, easy to work with and amenable to chemical and genetic conjugation to antigens such as MUC1. We compare here in mice the immunogenicity of MUC1 chemically conjugated to KLH or DHBcAg and MUC1-DHBcAg recombinant protein after an initial series of three vaccinations and then after an additional series of three vaccinations with the same or opposite carrier, all mixed with the saponin immunological adjuvant GPI-0100. High titer IgG antibodies were observed in all groups after the initial three vaccinations: MUC1-DHBcAg median ELISA titer 1/51200, RecMUC1-DHBcAg 1/25600 and MUC1-KLH 1/12800. This increased to 1/6553600 after the second set of three immunizations when the carrier remained the same in all three groups, but titers were significantly lower when the carriers were changed for the final three immunizations. These data demonstrate that DHBcAg is an excellent carrier protein and that changing carrier proteins does not further augment immunogenicity.
Collapse
Affiliation(s)
- John K Gathuru
- Laboratory of Tumor Vaccinology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
| | | | | | | | | | | | | |
Collapse
|
22
|
Meng FP, Ding J, Yu ZC, Han QL, Guo CC, Liu N, Fan DM. Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer. World J Gastroenterol 2005; 11:1833-6. [PMID: 15793876 PMCID: PMC4305886 DOI: 10.3748/wjg.v11.i12.1833] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To develop an oral attenuated Salmonella typhimurium vaccine against gastric cancer and to evaluate its efficacy in mice.
METHODS: A complementary sequence of Nco I site and a sequence coding for MG7-Ag mimotope were designed at the 5’ terminus of forward primer. Using p1.2 II-HBCAg plasmid as template, PCR was performed to get a fusion gene of the mimotope and a HBcAg gene. The fusion gene was then subcloned into the plasmid pYA3341 complementary to Salmonella typhimurium X4550, and the recombinant plasmid was then transformed into attenuated Salmonella typhimurium X4550. Balb/c mice were orally immunized with the recombinant Salmonella typhimurium X4550. The mice were immunized every 2 wk to reinforce the immunity. At the 6th wk, serum titer of antibody was detected by ELISA, and at the 8th wk, cellular immunity was detected by 51Cr release test. Ehrlich ascites carcinoma cells expressing MG7-Ag were used in tumor challenge assay as a model to evaluate the protective effect of the vaccine.
RESULTS: Serum titer of antibody against MG7-Ag was significantly higher in mice immunized with the vaccine than in control groups (0.9538±0.043 vs 0.6531±0.018, P<0.01; 0.9538±0.043 vs 0.6915±0.012, P<0.01), while in vitro51Cr release assay of the splenocytes showed no statistical difference in the three groups. Two weeks after tumor challenge, 1 in 5 immunized mice was tumor free, while all the mice in the control group presented tumor.
CONCLUSION: Oral attenuated Salmonella typhimurium vaccine against the MG7-Ag mimotope of gastric cancer is immunogenic. It can induce significant humoral immunity against tumors in mice, and has some protective effects.
Collapse
Affiliation(s)
- Fan-Ping Meng
- Institute of Digestive Disease, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, Shaanxi Province, China
| | | | | | | | | | | | | |
Collapse
|
23
|
Aguilar JC, Lobaina Y, Muzio V, García D, Pentón E, Iglesias E, Pichardo D, Urquiza D, Rodríguez D, Silva D, Petrovsky N, Guillén G. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol 2005; 82:539-46. [PMID: 15479440 DOI: 10.1111/j.0818-9641.2004.01278.x] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
There are estimated to be 350 million chronic carriers of hepatitis B infection worldwide. Patients with chronic hepatitis B are at risk of liver cirrhosis with associated mortality because of hepatocellular carcinoma and other complications. An important goal, therefore, is the development of an effective therapeutic vaccine against chronic hepatitis B virus (HBV). A major barrier to the development of such a vaccine is the impaired immune response to HBV antigens observed in the T cells of affected patients. One strategy to overcome these barriers is to activate mucosal T cells through the use of nasal vaccination because this may overcome the systemic immune downregulation that results from HBV infection. In addition, it may be beneficial to present additional HBV epitopes beyond those contained in the traditional hepatitis B surface antigen (HbsAg) vaccine, for example, by using the hepatitis B core antigen (HBcAg). This is advantageous because HBcAg has a unique ability to act as a potent Th1 adjuvant to HbsAg, while also serving as an immunogenic target. In this study we describe the effect of coadministration of HBsAg and HBcAg as part of a strategy to develop a more potent and effective HBV therapeutic vaccine.
Collapse
Affiliation(s)
- J C Aguilar
- Biomedical Branch, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
|
25
|
Aguilar JC, Acosta-Rivero N, Dueñas-Carrera S, Morales Grillo J, Pichardo D, Urquiza D, Guillen G, Muzio V. HCV core protein modulates the immune response against the HBV surface antigen in mice. Biochem Biophys Res Commun 2003; 310:59-63. [PMID: 14511648 DOI: 10.1016/j.bbrc.2003.08.120] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Mucosal vaccination is currently arousing a great deal of interest, since mucosally induced immunity is able to protect not only against microorganisms using mucosa as a door of entry, but also against those parenterally transmitted. Hepatitis C virus (HCV) is considered a worldwide health problem and a current vaccine is not available. In the present work, immunogenicity of particulate HCcAg was evaluated, administered alone and also in formulations with the main protective antigen of HBV, the surface antigen (HBsAg), both by mucosal (i.n.) and parenteral (i.m) routes. HCcAg was able to induce strong immune responses after nasal as well as parenteral administration, developing a strong Th1-like antibody response in serum. Preliminary data also suggested the ability of HCcAg to efficiently enhance and modulate the host immune response against HBsAg. These results support the use of the particulate HCcAg in the rational design of candidates for HCV therapeutic or preventive vaccine strategies or inclusively in the development of future combined vaccines.
Collapse
Affiliation(s)
- Julio C Aguilar
- Division of Vaccines, Center for Genetic Engineering and Biotechnology, PO Box 6162, CP 10600, C Havana, Cuba.
| | | | | | | | | | | | | | | |
Collapse
|